Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 450 Day Assessment Results for the First 13 Phase 2 Patients

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Feb 13, 2023 4:39pm

182 Views

Post# 35283878

RE:450 Day Assessment Results for the First 13 Phase 2 Patients

These results make a lot of sense given the posts of enriquesuave and consultant99. The 8 out of 12 patients who did not receive an optimized treatment were all NR at 450 days. And 3 of the 4 patients who received only one optimized treatment were either CR or PR at 450 days.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario